R428 (BGB324)
99%
- Product Code: 102237
CAS:
1037624-75-1
| Molecular Weight: | 506.64 g./mol | Molecular Formula: | C₃₀H₃₄N₈ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD21608463 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
R428 (BGB324) is primarily used in the field of oncology as a selective inhibitor of the AXL receptor tyrosine kinase. This receptor is often overexpressed in various types of cancer, contributing to tumor growth, metastasis, and resistance to chemotherapy. By inhibiting AXL, R428 has shown potential in reducing cancer cell proliferation and enhancing the effectiveness of other anticancer therapies. It is being investigated in clinical trials for its efficacy in treating solid tumors, including breast, lung, and pancreatic cancers. Additionally, R428 is being explored for its role in overcoming drug resistance in cancer treatment, offering a promising approach to improving patient outcomes.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Yellow Powder |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿4,590.00 |
+
-
|
| 0.005 | 10-20 days | ฿8,680.00 |
+
-
|
| 0.025 | 10-20 days | ฿21,100.00 |
+
-
|
| 0.100 | 10-20 days | ฿69,820.00 |
+
-
|
R428 (BGB324)
R428 (BGB324) is primarily used in the field of oncology as a selective inhibitor of the AXL receptor tyrosine kinase. This receptor is often overexpressed in various types of cancer, contributing to tumor growth, metastasis, and resistance to chemotherapy. By inhibiting AXL, R428 has shown potential in reducing cancer cell proliferation and enhancing the effectiveness of other anticancer therapies. It is being investigated in clinical trials for its efficacy in treating solid tumors, including breast, lung, and pancreatic cancers. Additionally, R428 is being explored for its role in overcoming drug resistance in cancer treatment, offering a promising approach to improving patient outcomes.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :